Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat...
This is the library for the Enduring Materials from the Targets for Cancer IO: A Deep Dive, iPSC derived cell therapies webinar that was conducted on September 26, 2022 . Moderators: Kalle Malmberg, MD, PhD - Oslo University Hospital Jeffrey S. Miller, MD - University of...
3 attachments
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in...
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions...
Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has...
On January 25, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma" during a live webinar. The recorded webinar and presentation slides...
2 attachments
On September 3, 2020, leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma" during a live webinar. The recorded webinar and presentation slides are...
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with...
From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Charleston event is provided here. The purpose of...
Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Charleston).mp4
LUNGevity's Patient Education Series offers several comprehensive booklets and brochures written and illustrated clearly to help patients understand their diagnosis and treatment options as well as the support services available through LUNGevity. These materials will help you learn about lung...